Qiagen and Eppendorf form alliance

Friday, 03 February, 2006

Qiagen and Eppendorf have announced that they have formed a strategic alliance that includes co-development and co-marketing of complementary and optimised products. The alliance is intended to link the brands and product lines and to ensure the highest compatibility of their products targeting the research, applied testing and molecular diagnostics.

In addition, Qiagen has acquired Eppendorf's reagent business which includes the Eppendorf's Prime nucleic acid sample preparation and PCR reagent product lines and related intellectual property. The acquired assets represent an attractive portfolio of preanalytical and nucleic acid amplification consumables as well as a very promising pipeline of proprietary technologies for nucleic acid handling, separation, purification and amplification.

Through the alliance, Qiagen and Eppendorf intend to focus on improving biological sample management and analysis. The availability of combined and optimised products should create significant benefits for customers in research, applied testing and molecular diagnostics.

Related News

Global competition targets 'undruggable' cancer protein

A new global competition offering over US$500,000 in prizes aims to spur drug discovery...

SMi Systems appoints Dr Ankur Mutreja as Senior Advisor

Mutreja was previously Head of Global South Partnerships at CEPI, where he was responsible for...

STA announces new Superstars of STEM, next President

Science & Technology Australia (STA) has announced the country's next Superstars of STEM,...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd